.png){kind=icon}
Return
Roflumilast
.png){kind=icon}
OA
AI
DOI：10.1038/nrd3276.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Keywords:
OBSTRUCTIVE PULMONARY-DISEASE
PDE4 INHIBITOR ROFLUMILAST
COPD
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
101.8
Papers:
5.1K
Citations:
5.3W
Organization
Cited Papers
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.png)
LANCET
LANCETIF88.5
PREAI
ShareSaveShareSaveManagement and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art reviewBMC MEDICINEOAAI
BMC MEDICINEIF8.3
OAAIShareSaveShareSaveRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLANCET
LANCETIF88.5
PREAI
ShareSaveShareSaveReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDTHORAXOAAI
THORAXIF7.7
OAAIShareSavePhosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary diseaseLANCET
LANCETIF88.5
PREAI
ShareSaveShareSave
View more